Ayala Pharmaceuticals Inc (ADXS)

[shub]

Trader, Neo is just barely clinical with a high probability of failure, a probable high cost of treatment and other companies developing neoantigen immuno products. Best case finds it 8 years away from approval.
Our other , more developed constructs should be of much greater value.
Only you traders want a buy out. The rest of us want to cash in on the fruits of our development.